Skip to main content

Advertisement

Table 3 Relative risks of breast cancer within 3 years of a negative mammographic screening result in relation to use of hormone replacement therapy, family history of breast cancer, and mammographic features

From: A clinical model for identifying the short-term risk of breast cancer

Study participant and mammographic features HRa (95% CI) HRb (95% CI)
Current use of HRT (same-year user vs. previous or nonuser) 1.4 (0.9–2.1) 1.3 (0.9–2.0)
Family history of breast cancer 1.3 (1.1–1.7) 1.3 (1.0–1.7)
Percentage mammographic density (cBIRADS 4 vs. 1) 4.9 (2.8–8.6) 4.8 (2.6–8.8)
Percentage mammographic density (per SD) 1.6 (1.4–1.8) 1.6 (1.4–1.8)
Number of microcalcificationsc (category 4 vs. 0) 2.0 (1.3–3.1) 2.0 (1.3–3.2)
Number of masses (4 vs. 0) 1.7 (0.8–3.5) 1.7 (0.8–3.5)
Individual absolute difference between breastsd
 Percentage mammographic density 3.4 (2.2–5.2) 1.9 (1.2–3.0)
 Number of microcalcifications 2.5 (1.9–3.1) 2.8 (1.8–4.5)
 Number of masses 1.4 (0.9–2.2) 1.1 (0.6–1.9)
  1. HRT Hormone replacement therapy
  2. aAdjusted for age, body mass index
  3. bAdjusted for age, body mass index, mammographic density, microcalcifications, masses, breast cancer in family, menopausal status, and current use of HRT
  4. cCategory 0 means 0 microcalcifications, and 1 is 1–10 microcalcifications. The corresponding numbers for 2, 3, and 4 are 11–20, 21–40, and >40 microcalcifications, respectively
  5. dAbsolute difference between right and left breasts was calculated as the standard deviation SD of the breasts for each mammographic feature